TG Therapeutics' Briumvi has shown strong revenue growth, with $310 million in FY24, and is expected to reach $540 million in ...

Learn more about whether Neurocrine Biosciences, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ ...

Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is ...

TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the ...

TG Therapeutics (TGTX) announced the presentation of data highlighting BRIUMVI in patients with relapsing forms of multiple sclerosis, at the ...

Norges Bank acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional ...

TG Therapeutics (TGTX) announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis ...

Learn more about whether Moderna, Inc. or TG Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

TG Therapeutics's revenues have an average growth rate of 333.9% with operating expenses growing at -6.5%. The company's ...

TG Therapeutics (TGTX) stock spikes as Roche (RHHBY) fails in a Phase 3 trial for a high dose version of its multiple ...

Detailed price information for Perspective Therapeutics Inc (CATX-A) from The Globe and Mail including charting and trades.

TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32. The stock has a market cap of $6.41 billion, a PE ratio of -407.86 and a beta of 2.30.